Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has scheduled its third quarter 2024 financial results announcement and corporate update for November 18, 2024, at 8:30 a.m. ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 with conference ID 80659, and a webcast will be available. A replay of the call will be accessible through the company's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biofarmaceutica in fase avanzata di sviluppo clinico focalizzata sul trattamento del cancro, ha programmato l'annuncio dei propri risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale per il 18 novembre 2024, alle 8:30 a.m. ET. L'azienda ospiterà una conferenza telefonica accessibile tramite il numero verde 1-800-717-1738 con ID conferenza 80659, e sarà disponibile anche una trasmissione web. Una registrazione della chiamata sarà accessibile attraverso il sito web delle relazioni con gli investitori della società.
Cellectar Biosciences (NASDAQ: CLRB), una empresa biofarmacéutica en etapa avanzada centrada en el tratamiento del cáncer, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 y una actualización corporativa para el 18 de noviembre de 2024, a las 8:30 a.m. ET. La empresa organizará una conferencia telefónica accesible a través del número gratuito 1-800-717-1738 con ID de conferencia 80659, y habrá una transmisión web disponible. Una repetición de la llamada estará accesible a través del sitio web de relaciones con inversores de la empresa.
Cellectar Biosciences (NASDAQ: CLRB), 암 치료에 중점을 둔 후기 임상 생명공학 회사는 2024년 3분기 재무 결과 발표와 기업 업데이트를 2024년 11월 18일 오전 8:30 ET로 예정했습니다. 회사는 1-800-717-1738의 광고 전화번호와 회의 ID 80659로 접근할 수 있는 컨퍼런스 콜을 개최하며, 웹캐스트도 이용 가능할 것입니다. 통화의 재생은 회사의 투자자 관계 웹사이트를 통해 접근할 수 있습니다.
Cellectar Biosciences (NASDAQ: CLRB), une société biopharmaceutique en phase avancée axée sur le traitement du cancer, a programmé l'annonce de ses résultats financiers du troisième trimestre 2024 et une mise à jour de l'entreprise pour le 18 novembre 2024 à 8h30 ET. L'entreprise tiendra une conférence téléphonique accessible via le numéro sans frais 1-800-717-1738 avec l'ID de conférence 80659, et un webinaire sera également disponible. Un enregistrement de l'appel sera accessible via le site des relations avec les investisseurs de la société.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Krebsbehandlung konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 sowie ein Unternehmensupdate für den 18. November 2024 um 8:30 Uhr ET angesetzt. Das Unternehmen wird eine Konferenzschaltung veranstalten, die über die kostenlose Nummer 1-800-717-1738 mit der Konferenz-ID 80659 zugänglich ist, und es wird auch einen Webcast geben. Eine Wiederholung des Anrufs wird über die Website für Investorenbeziehungen des Unternehmens zugänglich sein.
- None.
- None.
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Monday, November 18, 2024 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: | 80659 |
| Webcast: | Click HERE |
A replay of the call will be available on the Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC™) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes its lead asset, iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Additional radiotherapeutics are in development utilizing alpha emitters and Auger emitters to target solid tumors.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Christy Maginn
Bliss Bio Health
703-297-7194
cmaginn@blissbiohealth.com
INVESTORS:
Anne Marie Fields
Precision AQ (formerly Stern IR)
annemarie.fields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) report Q3 2024 earnings?
How can investors access CLRB's Q3 2024 earnings call?
What period will CLRB's financial results cover?
